Share this content on Facebook!
21 Dec 2016
A ray of hope is on the horizon for patients facing the debilitating effects of the muscle-wasting disease inclusion body myositis (IBM). University of Kansas Medical Center researchers conducting a joint study with the Medical Research Council (MRC) Centre for Neuromuscular Diseases at University College London are poised to take the next step in testing the drug, arimoclomol.

There is currently no Treatment of Inclusion Body Myositis, but research conducted by the KU/UCL partnership, published in the March 23 issue of Science Translational Medicine, revealed that the drug deserves further study on its potential to slow patients' crippling debilitation.

The most common muscle disease in people over 50, IBM is incurable and causes...